anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Olfactory dysfunction together with neurological and cognitive symptoms are common after COVID-19. We aimed to study whether performance on olfactory and neuropsychological tests following infection predict post-COVID condition (PCC), persisting symptoms, and reduced health-related quality of life.
METHODS: Both hospitalized (N = 10) and non-hospitalized individuals (N = 56) were enrolled in this prospective cohort study. Participants were evaluated 1-3 months after infection with an olfactory threshold test and neuropsychological tests, which was used as predictors of PCC. A questionnaire outlining persisting symptoms and the validated instrument EuroQol five-dimension five-level for health-related quality of life assessment were used as outcome data 1 year after infection (N = 59). Principal component analysis was used to identify relevant predictors for PCC at 1 year.
RESULTS: Objectively assessed olfactory dysfunction at 1-3 months post infection, but not subjective olfactory symptoms, predicted post-COVID condition with reduced health-related quality of life (PCC+) at 1 year. The PCC+ group scored more often below the cut off for mild cognitive impairment on the Montreal Cognitive Assessment (61.5% vs. 21.7%) and higher on the Multidimensional Fatigue Inventory-20, compared to the group without PCC+.
CONCLUSION: Our results indicate that objectively assessed, olfactory dysfunction is a predictor for PCC+. These findings underscore the importance of objective olfactory testing. We propose that olfactory screening in the early post-acute phase of COVID-19 infection might identify individuals that are at higher risk of developing long-term health sequalae.
Subjects in the control group were given a placebo, which was the same shape of bean powder(600mg/d, q.d.) for 6 months.
This study aimed to assess the impact of an interactive spelling program on reading acquisition of children at risk of developing reading difficulties as well as to assess its effect on spelling and phonemic awareness. From an initial pool of 144 first-grade children attending four Portuguese primary schools, 53 children with low performances in letter knowledge and phonemic awareness tasks, and considered by their teachers to be at risk of developing reading difficulties, were selected. These children were randomly assigned to three groups: an experimental group that underwent an interactive spelling program, a comparison group that underwent a phonological awareness program, and a control group that underwent a copying program. The programs, conducted in pairs, comprised 12 sessions lasting 20 to 30 min twice a week. The pretest and posttest included word reading, word spelling, and phonemic awareness assessments. Data analysis showed that the spelling group significantly outperformed the other groups across all measures except in the phonemic awareness task, where there were no differences with the phonological group. The word copying group consistently yielded the lowest results. Unlike the other two groups, the posttest results of the experimental group also reached the class average in word reading. For ethical reasons, after the final assessments the control group underwent a version of the interactive spelling program. This study suggests that spelling activities can contribute significantly to reading acquisition and can serve as a valuable pedagogical tool to proactively address challenges in learning to read.
SEROQUEL XR (quetiapine fumarate) is an atypical antipsychotic belonging to a chemical class, the dibenzothiazepine derivatives. The chemical designation is 2-[2-(4-dibenzo [ ] [1,4] thiazepin-11-yl-1-piperazinyl)ethoxy]-ethanol fumarate (2:1) (salt). It is present in tablets as the fumarate salt. All doses and tablet strengths are expressed as milligrams of base, not as fumarate salt. Its molecular formula is C H N O S •C H O and it has a molecular weight of 883.11 (fumarate salt). The structural formula is: b,f4250642444

Quetiapine fumarate is a white to off-white crystalline powder which is moderately soluble in water.

SEROQUEL XR is supplied for oral administration as 50 mg (peach), 150 mg (white), 200 mg (yellow), 300 mg (pale yellow), and 400 mg (white). All tablets are capsule shaped and film coated.

Inactive ingredients for SEROQUEL XR are lactose monohydrate, microcrystalline cellulose, sodium citrate, hypromellose, and magnesium stearate. The film coating for all SEROQUEL XR tablets contain hypromellose, polyethylene glycol 400 and titanium dioxide. In addition, yellow iron oxide (50, 200 and 300 mg tablets) and red iron oxide (50 mg tablets) are included in the film coating of specific strengths.

Each 50 mg tablet contains 58 mg of quetiapine fumarate equivalent to 50 mg quetiapine. Each 150 mg tablet contains 173 mg of quetiapine fumarate equivalent to 150 mg quetiapine. Each 200 mg tablet contains 230 mg of quetiapine fumarate equivalent to 200 mg quetiapine. Each 300 mg tablet contains 345 mg of quetiapine fumarate equivalent to 300 mg quetiapine. Each 400 mg tablet contains 461 mg of quetiapine fumarate equivalent to 400 mg quetiapine.
Preoperative nabuliumab combined with FLOT and trastuzumab + surgical treatment + postoperative nabuliumab combined with FLOT and trastuzumab. There were 4 cycles before and after surgery, one cycle every 2 weeks. The specific administration was: docetaxel 50mg/m2 iv,d1, oxaliplatin 85mg/m2 iv,d1, calcium leucovorin 200mg/m2 iv,d1,5-FU 2600mg/m2 iv,d1, infusion 24h; Nebulizumab 240mg iv,d2, 30 minutes per intravenous infusion, trastuzumab 4mg/kg iv,d2 (load dose 6mg /kg).
The present invention relates to a sophora root extract microcapsule containing a biodegradable polymer, and a skin whitening cosmetic composition containing the same. More specifically, a content of kurarinone is standardized to be included in a sophora root extract in a particular range, and when being applied to the human body, the sophora root extract has an excellent whitening effect, thereby being used in skin whitening cosmetics. The present invention relates to a sophora root extract-containing microcapsule, in which a sophora root extract is included in a biodegradable polymer. The sophora root extract contains 0.001-50 wt% of kurarinone as an indicator material. Moreover, a biodegradable polymer constituting a wall material of the sophora root extract-containing microcapsule is polylactic acid, polymethylmethacrylate, and polycaprolactone. A weight ratio of polylactic acid, polymethylmethacrylate, and polycaprolactone is 7-8:2-3:1-2.
The invention relates to application of Eryngiolide A in preparing a medicine for promoting small intestine peristalsis. The invention provides application of Eryngiolide A in preparing the medicine for promoting small intestine peristalsis. Pharmacological tests prove that Eryngiolide A has favorable function of promoting small intestine peristalsis. The application of Eryngiolide A in preparing the medicine for promoting small intestine peristalsis, which is provided by the invention, is disclosed for the first time. The skeleton type belongs to brand-new skeleton type, and the small intestine peristalsis promoting activity of Eryngiolide A is extremely strong, so that no possibility for providing any prompt by other compounds exists. Eryngiolide A has outstanding actual characteristics. Meanwhile, Eryngiolide A has outstanding progress in preparing the medicine for promoting small intestine peristalsis.
Acute gastro-esophageal variceal hemorrhage is a dreadful complication of portal hypertension. Meta-analysis showed that the combination of vasoconstrictor and endoscopic therapy is superior to endoscopic therapy or vasoconstrictor alone in the control of acute esophageal variceal hemorrhage. Bacterial infections are frequently encountered in cirrhotic patients presenting with acute upper gastrointestinal bleeding. The association of bacterial infections to variceal bleeding may increase the occurrence of variceal rebleeding and mortality. A study has shown that antibiotic prophylaxis in patients with acute esophageal variceal hemorrhage may reduce infection as well as prevent rebleeding. Currently, most guidelines recommend that vasoactive drugs should be continued for 3 to 5 days after endoscopic therapy and antibiotics should be instituted for up to 7 days to manage patients with acute esophageal variceal hemorrhage . On the other hand, some studies in recent years implied that short term vasoconstrictors or antibiotics could achieve similar low variceal rebleeding rates. The use of prophylactic antibiotics in cirrhotics with gastrointestinal bleeding for only one single dose or 3 days appeared to be feasible. It is still unknown whether use of short term both vasoconstrictors and antibiotics could have similar acute hemostatic rate.

Thus, the investigators conducted a trial to compare the effectiveness between participants receiving terlipressin and ceftriaxone 5 days and terlipressin and ceftriaxone 2 days after endoscopic therapy in cirrhotic patients presenting with acute gastroesophageal variceal hemorrhage..
Patients with advanced chronic kidney disease (CKD) have elevated circulating calcium × phosphate product levels and exhibit soft tissue calcification. Besides the cardiovascular system, calcification is commonly observed in the cornea in CKD patients on hemodialysis. Cardiovascular calcification is a cell-mediated, highly regulated process, and we hypothesized that a similar regulatory mechanism is implicated in corneal calcification with the involvement of corneal epithelial cells (CECs). We established a mouse model of CKD-associated corneal calcification by inducing CKD in DBA/2J mice with an adenine and high phosphate diet. CKD was associated with aorta and corneal calcification as detected by OsteoSense staining and corneal Ca measurement (1.67-fold elevation, p < 0.001). In vitro, excess phosphate and Ca induced human CEC calcification in a dose-dependent and synergistic manner, without any influence on cell viability. High phosphate and Ca-containing osteogenic medium (OM; 2.5 mmol/L excess phosphate and 0.6 mmol/L excess Ca over control) increased the protein expression of Runx2 and induced its nuclear translocation. OM increased the expression of the bone-specific Ca-binding protein osteocalcin (130-fold increase, p < 0.001). Silencing of Runx2 attenuated OM-induced CEC calcification. Immunohistology revealed upregulation of Runx2 and overlapping between the Runx2 and the Alizarin red positive areas of calcification in the cornea of CKD mice. This work sheds light on the mechanism of CKD-induced corneal calcification and provides tools to test calcification inhibitors for the prevention of this detrimental process.
BACKGROUND: We aimed to determine the prevalence and severity of glomerular and tubular renal dysfunction by means of urinalysis in infants and toddlers with congenital cytomegalovirus infection (cCMV) and their association with cCMV disease, viruria and antiviral treatment.
METHODS: This cross-sectional study was done using the Spanish Registry of Congenital Cytomegalovirus Infection. First-morning urine samples were collected from January 2016 to December 2018 from patients <5 years old enrolled in Spanish Registry of Congenital Cytomegalovirus Infection. Samples were excluded in case of fever or other signs or symptoms consistent with acute infection, bacteriuria or bacterial growth in urine culture. Urinary protein/creatinine and albumin/creatinine ratios, urinary beta-2-microglobulin levels, hematuria and CMV viruria were determined. A 0.4 cutoff in the urinary albumin/protein ratio was used to define tubular (<0.4) or glomerular (>0.4) proteinuria. Signs and symptoms of cCMV at birth, the use of antivirals and cCMV-associated sequelae at last available follow-up were obtained from Spanish Registry of Congenital Cytomegalovirus Infection.
RESULTS: Seventy-seven patients (37 females, 48.1%; median [interquartile range] age: 14.0 [4.4-36.2] months) were included. Symptom-free elevated urinary protein/creatinine and albumin/creatinine ratios were observed in 37.5% and 41.9% of patients, respectively, with tubular proteinuria prevailing (88.3%) over glomerular proteinuria (11.6%). Proteinuria in the nephrotic range was not observed in any patients. In multivariate analysis, female gender was the only risk factor for tubular proteinuria (adjusted odds ratio = 3.339, 95% confidence interval: 1.086-10.268; P = 0.035). cCMV disease at birth, long-term sequelae, viruria or the use of antivirals were not associated with urinalysis findings.
CONCLUSIONS: Mild nonsymptomatic tubular proteinuria affects approximately 40% of infants and toddlers with mostly symptomatic cCMV in the first 5 years of life.
PURPOSE: To provide a safe and novel immune agent which consists of the pure capsule polysaccharides formed by making the lipopolysaccharide contained therein nontoxic by a treatment with a deacylating agent and is useful for active immunity to a Klebsiella infection. CONSTITUTION: The polyvalent immune pharmaceutical prepn. consisting of a nontoxic serum type specific polysaccharide prepn. Namely, the refined capsule polysaccharide(CPS) derived from the bacteria of Klebsiella species are treated with the deacylating agent, such as potassium hydroxide, by which the nonexothermic immunogenic CPS pharmaceutical prepn. is obtd. The Klebsiella infectious disease may be prevented by using the immunogenic Klebsiella species CPS. The capsule polysaccharides are preferably refined from the clean matter in terms of culture of the Klebsiella cultured in a medium consisting of 1 to 5% pie cases S, F, 0.1 to 1% yeast extract and 1 to 10% maltose. The average mol.wt. of the capsule polysaccharide is preferably 1×10<6> dalton. The vaccine is nonorally medicated in order to increase the serum antibody level to the CPS.
The present invention relates to a pharmaceutical composition and a method for producing the same, wherein the pharmaceutical composition comprises a nonsteroidal anti-inflammatory drug (NSAID); forms a film when applied to a wound, and thus is convenient to use; has maximized absorption; and causes little skin irritations. Unlike the conventional topical agent which is sticky to touch or easily gets on clothes, etc. the pharmaceutical composition according to the present invention, when applied to a wound, quickly forms a film and thus is convenient to use. In addition, the pharmaceutical composition can be easily applied to finger joints, knees, elbows, and other areas where it is difficult to apply patches, such as a plaster. In addition, the present invention can maximize therapeutic efficacy by significantly increasing the drug absorption to a wound from formulations. In addition, the present invention causes little skin irritations, and thus can minimize abnormal skin symptoms such as rash, etc. even when applied to the skin for a long time. Accordingly, the present invention can provide a convenient-to-use and effective pharmaceutical composition for those patients that expect analgesic and anti-inflammatory effects for the symptoms of osteoarthritis, adhesive capsulitis of shoulder, myalgia, and tenosynovitis.
The invention provides a preparation method of burdock fruit formula particles. Adding fructus Arctii decoction pieces into boiling water according to a preset proportion, and extracting arctiin. Under the high temperature of water, the biological enzyme structure of arctiin hydrolysis is damaged, and then the arctiin in arctiin is deactivated, so that arctiin in arctiin can not be hydrolyzed rapidly. The loss of the biological enzyme activity reduces the hydrolysis of arctiin, so that the content of arctiin in the extract is improved, and the transfer rate is improved. When the burdock decoction pieces are decocted, the burdock decoction pieces are swelled, water outside the burdock tissues enters the tissues, and a higher-concentration arctiin solution is formed inside the tissues. Because of the difference of the internal concentration and the external concentration, the arctiin solution with high concentration in the tissue permeates outside the tissue, and the arctiin in the arctiin decoction pieces can be dissolved in water more quickly and completely, so that the transfer rate of the arctiin is further improved.
A process for the preparation of a fibrinogen-reduced antihaemophilic globulin (A.H.G.) solution comprises treating an aqueous buffered solution of mammalian blood plasma or a crude concentrate containing A.H.G. derived therefrom at a pH of 6 to 8 with an ion exchanger whereby only a proportion of the total available protein, controllable by adjustment of the ionic strength of the solution, is adsorbed, but that this adsorption is selective for the A.H.G. component, followed by washing the ion exchanger free from unadsorbed material with an aqueous buffer solution at the same pH and of the same ionic strength or slightly less than that employed for adsorption then followed by eluting with an aqueous salt or buffer solution at a greatly increased ionic strength to that of the original aqueous buffer solution and within the pH range 6-8 to produce the purified A.H.G. solution in which the A.H.G. is associated with less fibrinogen than was the original solution. Specified ion exchangers are carboxylic ion exchange resins derived from methacrylic acid and cross-linked with divinyl benzene, basic ion exchange resins derived from cross-linked polystyrene carrying quaternary ammonium groups and cellulose derivatives carrying diethylaminoethyl groups.  Aqueous phosphate buffers e.g. sodium phosphate and citrate-phosphate buffers are used as buffers.  For acidic exchangers when adsorbing, the buffer should be at a molarity of 0.2-0.3 M and for basic exchangers at a molarity of 0.15-0.5 M. Elution from an acidic exchanger is facilitated by increasing the pH and from a basic exchanger by lowering the pH.  The eluting phosphate buffer solution should be of a molarity of 0.6-0.7 M or alternatively a 4-6% solution of sodium chloride buffered with phosphate pH 7, molarity 0.1 M, may be used.
Automatic seizure detection plays a key role in assisting clinicians for rapid diagnosis and treatment of epilepsy. In view of the parallelism of temporal convolutional network (TCN) and the capability of bidirectional long short-term memory (BiLSTM) in mining the long-range dependency of multi-channel time-series, we propose an automatic seizure detection method with a novel end-to-end TCN-BiLSTM model in this work. First, raw EEG is filtered with a 0.5-45 Hz band-pass filter, and the filtered data are input into the proposed TCN-BiLSTM network for feature extraction and classification. Post-processing process including moving average filtering, thresholding and collar technique is then employed to further improve the detection performance. The method was evaluated on two EEG database. On the CHB-MIT scalp EEG database, our method achieved a segment-based sensitivity of 94.31%, specificity of 97.13%, and accuracy of 97.09%. Meanwhile, an event-based sensitivity of 96.48% and an average false detection rate (FDR) of 0.38/h were obtained. On the SH-SDU database we collected, the segment-based sensitivity of 94.99%, specificity of 93.25%, and accuracy of 93.27% were achieved. In addition, an event-based sensitivity of 99.35% and a false detection rate of 0.54/h were yielded. The total detection time consumed for 1[Formula: see text]h EEG data was 5.65[Formula: see text]s. These results demonstrate the superiority and promising potential of the proposed method in real-time monitoring of epileptic seizures.
The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1' position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety. Indolinone compounds that are modified with substituents, particularly at the 5 position of the oxindole ring, can effectively activate protein kinases. This invention also features novel hydrosoluble indolinone compounds that are tyrosine kinase inhibitors and related products and methods.
BACKGROUND: Neurological complications have been observed in approximately 30% of hospitalized COVID-19 patients. The aim of this study was to evaluate whether early assessment of the Neurological Pupil Index (NPiTM) derived from an automated pupillometry could predict mortality in critically ill COVID-19 patients.
METHODS: Retrospective cohort study of adult critically ill COVID-19 patients admitted to the intensive care unit of a University Hospital; patients without NPi measurement were excluded. The worst NPi (i.e. lowest value from one eye) was collected daily and then computed over the first five days of assessment. Mortality was assessed at hospital discharge. The secondary endpoint involved assessing differences in neurological assessments between patients who developed neurological complications and those who did not.
RESULTS: A total of 217 patients were included over the study period (median age 61 [50-68] years), 70% were males. A total of 97 patients (45%) died during the hospital stay. Among all patients, 35 (16%) experienced neurological complications. Non-survivors showed significantly a lower overall NPi (3.0 [2.0-4.1] vs. 3.4 [2.7-4.2]; P=0.04) than survivors. At multivariate logistic regression NPi was not significantly associated with in-hospital mortality. Moreover, no differences in different NPi measurements were observed between patients with and without neurological complications.
CONCLUSIONS: In this study, NPi values were not independent predictor of mortality and neurological complications in critically ill COVID-19 patients.
Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including Salsalate tablet, USP. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy.

Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes have been reported.

A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with Salsalate tablet, USP. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), Salsalate tablet, USP should be discontinued.